ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharma (ANIP) Tops Q3 EPS by 11c, Offers Guidance
November 9, 2022 7:28 AM ESTANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.64, $0.11 better than the analyst estimate of $0.53. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $77.2 million.
GUIDANCE:
ANI Pharma sees FY2022 EPS of $1.34-$1.62, versus the consensus... More
